INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC

/EIN News/ -- ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) complied with federal securities laws. On May 16, 2025, the FDA stated: “Given that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.” Following this news, the price of the Company’s stock dropped. 

If you purchased UroGen stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/urogen-pharma/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  
  
CONTACT:  
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com